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Abstract 25 
This study assessed the metabolic and neuroprotective actions of the sodium glucose co-transporter-26 
2 inhibitor dapagliflozin in combination with the GLP-1 agonist liraglutide in dietary-induced 27 
diabetic mice. Mice administered low-dose streptozotocin (STZ) on a high fat diet received 28 
dapagliflozin, liraglutide, dapagliflozin-plus-liraglutide (DAPA-Lira) or vehicle once-daily over 28 29 
days. Energy intake, body weight, glucose and insulin concentrations were measured at regular 30 
intervals. Glucose tolerance, insulin sensitivity, hormone and biochemical analysis, dual-energy x-31 
ray absorptiometry densitometry, novel object recognition, islet and brain histology were examined. 32 
Once-daily administration of DAPA-Lira resulted in significant decreases in body weight, fat mass, 33 
glucose and insulin concentrations, despite no change in energy intake. Similar beneficial metabolic 34 
improvements were observed regarding glucose tolerance, insulin sensitivity, HOMA-IR, HOMA-β, 35 
HbA1c, and triglycerides. Plasma glucagon, GLP-1 and IL-6 levels were increased and 36 
corticosterone concentrations decreased. DAPA-Lira treatment decreased alpha cell area and 37 
increased insulin content compared to dapagliflozin monotherapy. Recognition memory was 38 
significantly improved in all treatment groups. Brain histology demonstrated increased staining for 39 
doublecortin (number of immature neurons) in dentate gyrus and synaptophysin (synaptic density) 40 
in stratum oriens and stratum pyramidale. These data demonstrate that combination therapy of 41 
dapagliflozin and liraglutide exerts beneficial metabolic and neuroprotective effects in diet-induced 42 
diabetic mice. Our results highlight important personalised approach in utilising liraglutide in 43 
combination with dapagliflozin, instead of either agent alone, for further clinical evaluation in 44 
treatment of diabetes and associated neurodegenerative disorders.  45 
 46 
Keywords: dapagliflozin; diabetes; GLP-1; glucagon; liraglutide  47 
 48 
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Introduction 49 
Type 2 diabetes mellitus (T2DM) is a metabolic disorder that arises due to a complex array of 50 
molecular defects manifesting in dysregulated insulin secretion, impaired insulin action, or both. 51 
Since the pathophysiology of T2DM is multifaceted and involves a range of biochemical 52 
mechanisms, there is no single therapy can effectively manage all aspects of the disorder (Zaccardi 53 
et al. 2016). Moreover, as T2DM and obesity levels are increasing at an alarming rate, more 54 
effective therapies and innovative treatment strategies are urgently needed to control glycaemia, 55 
reduce body weight and decrease the risk of micro- and macrovascular complications (da Rocha 56 
Fernandes et al. 2016). The previous two decades have witnessed a surge in the number of new drug 57 
classes such as glucagon-like peptide-1 (GLP-1) agonists, dipeptidylpeptidase-4 (DPP4) inhibitors 58 
and sodium-glucose-cotransporter-2 (SGLT2) inhibitors (Bailey et al. 2016). Although these agents 59 
may be used as monotherapies, it is becoming increasingly apparent that successful and cost 60 
effective management of T2DM requires development of safe combination therapies with distinct 61 
and complementary mechanisms of action. 62 
The kidneys play a pivotal role in regulating glucose homeostasis as most of the glucose 63 
filtered by the glomerulus is reabsorbed (Gerich et al. 2001). In healthy subjects, the high capacity, 64 
low-affinity SGLT2, reabsorbs approximately 90% of glucose in S1 segment of proximal tubules 65 
(Hediger & Rhoads 1994, Han et al. 2008). Under conditions of chronic hyperglycaemic, SGLT2 is 66 
up regulated and this enhances glucose reabsorption and worsens glycaemia (Rahmoune et al. 67 
2005). Dapagliflozin, a highly selective and potent oral inhibitor of SGLT2, reduces reabsorption of 68 
filtered glucose leading to increased glucosuria and improvement in glycaemic control (Vivian 69 
2015). Although actions of dapagliflozin appear to be independent of insulin secretion, dapagliflozin 70 
improves insulin sensitivity, most likely as a result of sustained reduction in hyperglycaemia, 71 
alleviation of glucose toxicity and weight reduction through enhanced caloric loss (Macdonald et al. 72 
Page 3 of 40
 4
2010, Mudaliar et al. 2014, Merovci et al. 2015, Millar et al. 2016). Beneficial actions of 73 
dapagliflozin are, to some extent, limited by unrestrained hepatic glucose production (Bonner et al. 74 
2015). Thus, inhibition of hepatic glucose output by stimulation of insulin secretion as well as 75 
inhibition of glucagon secretion may significantly enhance therapeutic efficacy of SGLT2 76 
inhibition. 77 
GLP-1 agonists are well established as effective agents to treat patients with T2DM due to a 78 
range of beneficial actions including weight loss, induction of satiety, inhibition of gastric emptying, 79 
stimulation of insulin secretion and inhibition of alpha cell function (Bailey et al. 2016). In addition, 80 
GLP-1 agonists exert effects at other extra pancreatic sites (Renner et al. 2016), with notable 81 
neuroprotective actions in animal models of diabetes-obesity, Alzheimer’s disease (AD) and 82 
Parkinson’s disease (PD) (Ashraghi et al. 2016, Tramutola et al. 2017). Liraglutide (Victoza) is a 83 
highly effective long-acting GLP-1 agonist that shares 97% sequence homology with human GLP-1 84 
(Knudsen et al. 2000). Structural modifications include amino acid substitution of Lys34 with Arg, 85 
and addition of lipophilic C16 acyl moiety at position 26 via gamma-glutamyl linker (Madsen et al. 86 
2007). These structural changes provide liraglutide with enhanced pharmacokinetic profile and 87 
significantly prolonged half-life, thus facilitating once-daily injection (Agersø et al. 2002). This 88 
prolonged bioactivity has been attributed to non-covalent reversible albumin binding, ability of 89 
liraglutide to self-aggregate and form heptamers in solution, and stability to the enzyme DPP4 90 
(Knudsen et al. 2000, Madsen et al. 2007, Li et al. 2016). 91 
Given the need for more personalised treatment strategies for patients with T2DM and the 92 
unique mechanism of action of dapagliflozin and liraglutide, we hypothesised that combining both 93 
drugs would provide additive metabolic and neuroprotective outcomes. We chose to administer a 94 
GLP-1 agonist rather than DPP-4 inhibitor as DPP-4 inhibitors act to prevent degradation of a 95 
number of regulatory peptides including GLP-1 (Bailey et al. 2016). As such, HF mice on 96 
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background low-dose STZ were treated with dapagliflozin or liraglutide as monotherapy and 97 
combination therapy for 28 days. Effects on glucose tolerance, insulin sensitivity, body weight, 98 
hormones, memory and learning, islet and brain histology were assessed. 99 
 100 
Materials and methods 101 
Animals  102 
Male NIH Swiss mice (aged 8-10 weeks) purchased from Harlan (Oxon, UK) were kept at 22±2ºC 103 
with 12:12 h light/dark cycle. Mice had free access to high fat diet (45% AFE Fat; Product Code 104 
824053; Special Diet Services, Witham, UK; total energy 26.15 kJ/g). An additional group of mice 105 
had free access to standard rodent chow (Teklad Global 18% Protein Rodent Diet; Product Code 106 
2018S; Harlan, UK; total energy 13.0 kJ/g). All animals had free access to drinking water and no 107 
adverse effects were observed during the entire experimental study. All experiments were performed 108 
according to the Principles of Laboratory Animal Care (NIH publication no. 86-23, revised 1985) 109 
and UK Home Office Regulations (UK Animals Scientific Procedures Act 1986). 110 
 111 
Experimental design  112 
Mice commenced high fat diet on day -28 and subsequently received STZ (Sigma-Aldrich, Dorset, 113 
UK) prepared in sodium citrate buffer (pH 4.5) on day -14 (50 mg/kg; i.p.) and day -7 (50 mg/kg; 114 
i.p.). Mice that displayed a blood glucose concentration greater than 13 mmol/l were recruited into 115 
the study. On day 0, mice commenced drug treatments for 28 days as follows: Group 1 (HF control) 116 
– high fat mice administered saline vehicle (0.9% wt/vol; p.o.; o.d.); Group 2 (dapagliflozin) – high 117 
fat mice administered dapagliflozin (1 mg/kg; p.o.; o.d.; Selleck Chemicals; Stratech Scientific Ltd., 118 
Suffolk, UK; Catalog number S1548-SEL);  Group 3 (DAPA-Lira) – high fat mice administered 119 
dapagliflozin (1 mg/kg; p.o.; o.d.) plus liraglutide (25 nmol/kg; i.p.; o.d.;  GL Biochem Ltd., 120 
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Shanghai, China); Group 4 (Lira) - high fat mice administered liraglutide (25 nmol/kg; i.p.; o.d.); 121 
Group 5 (lean control) – lean mice administered saline vehicle (0.9% wt/vol; p.o.; o.d.). All 122 
treatments administered at 14:00 h and mice remained on respective diet for study duration. The 123 
rationale for choosing 1 mg/kg dapagliflozin (p.o.) and 25 nmol/kg liraglutide (i.p.) in this study was 124 
based on previously published literature (Moffett et al. 2014, Millar et al. 2016). Energy intake, 125 
body weight, glucose and insulin concentrations were measured every 3 to 4 days. At the end of the 126 
study, glucose tolerance (18 mmol/kg; p.o.; at 10:00 h in 12 h-fasted mice), insulin sensitivity (25 127 
U/kg bovine insulin; i.p.; at 10:00 h in non-fasted mice), novel object recognition task, dual-energy 128 
x-ray absorptiometry (DEXA) scanning, lipids, hormones/biomarkers, islet and brain histology were 129 
performed.  130 
 131 
Biochemical and DEXA analyses  132 
Blood samples were collected as indicated in Figures from tail vein of conscious mice into chilled 133 
fluoride/heparin micro-centrifuge tubes (Sarstedt, Numbrecht, Germany) and centrifuged at 13,000g 134 
for 30 s (Beckman Instruments, Galway, Ireland). Glucose concentrations were measured using 135 
Ascencia Contour Blood Glucose Meter (Bayer Healthcare, Newbury, UK) and plasma/pancreatic 136 
insulin determined using modified dextran-coated charcoal RIA (Flatt & Bailey 1981). HOMA-IR 137 
and HOMA-β were determined from calculations as described previously (Gault et al. 2015). Lipids 138 
(total-cholesterol – CH200; and triglycerides – TR210) and ALT (AL1205) were measured using 139 
enzymatic kits from Randox Laboratories (Crumlin, UK). Plasma corticosterone (ab100712) and IL-140 
6 (ab108821) were measured using enzymatic kits from Abcam (Cambridge, UK) and analysed with 141 
SOFTMAX PRO Software Version 5.2 on Flexstation 3 (Molecular Devices, Sunnyvale, CA, USA). 142 
Glucagon and total GLP-1 were measured by ELISA (EZGLU-30K and EZGLP1T-36K, 143 
respectively; Millipore, UK). HbA1c was determined with a commercially available kit (HB-3058; 144 
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Chirus Limited, Watford, UK). Percentage fat and lean mass were measured using DEXA 145 
densitometry (Piximus Densitometer, USA) as described previously (Millar et al. 2016).  146 
 147 
Assessment of learning and memory  148 
Open field and novel recognition tests were performed as described previously (Lennox et al. 2014). 149 
Briefly, mice were placed in an arena and motor activity (speed and path length), anxiety (grooming 150 
events) and exploration (rearing events) recorded over 5 min period. Twenty-four hours later, mice 151 
were placed back into the same arena and a novel object recognition task was conducted comprising 152 
a 10 min acquisition phase (followed by a 3 h rest in the home cage) followed by test trial where 153 
mice could explore familiar and novel object for 10 min. Time spent exploring familiar or novel 154 
object was expressed as recognition index (RI) calculated as time (t) spent exploring novel object 155 
divided by time spent exploring both objects (A + B) x 10. RIB = tB/t(A + B) x 100 normalises all 156 
data for statistical comparison (Lennox et al. 2014). 157 
 158 
Immunohistochemistry and image analysis  159 
Mice were perfused with PBS transcardially as described previously (Parthsarathy et al. 2013). 160 
Pancreatic tissue was excised for immunohistochemistry, measurement of insulin/glucagon content 161 
and gene expression. For determination of pancreatic insulin and glucagon content, pre-weighed 162 
pancreatic tissue was washed thoroughly in ice-cold PBS, homogenised in acid ethanol solution 163 
(ethanol/0.7 M HCl; 3:1 ratio) and extracted overnight at 4°C. Insulin content was measured by 164 
insulin radioimmunoassay and glucagon content determined by ELISA (EZGLU-30K; Millipore, 165 
UK). For histology, pancreatic tissues were fixed in 4% paraformaldehyde for 48 h at 4°C, 166 
processed using automated tissue processor (Leica TP1020, Leica Microsystems, Nussloch, 167 
Germany) and embedded in paraffin wax. Immunohistochemistry was performed as described 168 
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previously (Moffett et al. 2015). Following primary antibodies used: mouse monoclonal anti-insulin 169 
antibody (ab6995, 1:1000; Abcam), guniea-pig anti-glucagon antibody (PCA2/4, 1:400; raised in-170 
house), rabbit polyclonal anti-GLP-1 antibody (XJIC8, 1:200; raised in-house) and mouse 171 
polyclonal anti-IL-6 details (PM626, 1:200; ThermoFisher Scientific). Secondary antibodies used as 172 
appropriate: Alexa Fluor 488 goat anti-guinea pig IgG – 1:400, Alexa Fluor 594 goat anti-mouse 173 
IgG – 1:400. Slides were viewed under FITC filter (488 nm) or TRITC filter (594 nm) using 174 
fluorescent microscope (Olympus BX51) and DP70 camera adapter system. Brain processing and 175 
immunostaining were performed as described previously (Parthsarathy et al. 2013). Briefly, 40 176 
micron thick coronal sections of brains at anatomical regions -2 to -3 bregma were stained for young 177 
immature neurons (anti-doublecortin, 1:200 dilution, sc-8066, Santa Cruz Biotechnology) and 178 
synaptic density (anti-synaptophysin, 1:200 dilution, Abcam, ab-7837).  179 
 180 
Image analysis 181 
Alpha and beta cell area were analysed in a blinded manner using Cell^F image analysis software 182 
(Olympus Soft Imaging Solutions, GmbH) and expressed as µm2. Briefly, fluorescent images were 183 
captured using digital camera and closed polygon tool in Cell^F used to analyse alpha cell and beta 184 
cell area. Pixel area was converted to µm2 and plotted in Prism. To quantify cell proliferation and 185 
neurogenesis, DCX-labelled immature neurons were counted in sub granular zone of dentate gyrus. 186 
Minimum of seven coronal sections per animal were counted using 40 x objective of bright field 187 
microscope (Olympus BX51) and plotted as average number of positive cells per section. 188 
Synaptophysin staining was analysed with Image J (NIH, USA) software using corrected O.D. 189 
method (McClean et al. 2011). Briefly, following adjustment for optimum resolution, calibration for 190 
optical density was performed using Kodak No. 3 step tablet (Tiffen, Kodak) and calibration curve 191 
obtained as described in Image J software. Using 10 x magnification objective, image for each area 192 
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of interest was obtained per section (4-5 sections per mouse brain) with digital camera. Area of 193 
interest comprised hippocampus and cortex that included polymorphic layer, granular cell layer, 194 
molecular layer, stratum radiatum, stratum pyramidal, stratum oriens, interior and exterior cortical 195 
layers. Images were converted to 8-bit grey scale and pixel density obtained from three small 196 
randomly selected squares per layer converted to O.D. using calibration curve. Average O.D values 197 
for each layer were subtracted from average O.D values of granular cell layer (GCL) and corrected 198 
O.D. plotted. 199 
 200 
Gene expression  201 
mRNA extracted (Tripure Isolation Reagent; Roche Diagnostics, UK), quantified and purity 202 
determined using nanophotometer (Implen, Munich, Germany). cDNA synthesized using 203 
Transcriptor First Strand cDNA Synthesis Kit (Roche Diagnostics) and gene expression analysis for 204 
insulin and glucagon performed on whole pancreas by qPCR using Light Cycler 480 Probes Master 205 
(Roche Diagnostics) according to manufacturer's instructions (Gault et al. 2015). HPRT and beta-206 
actin were used as internal control for normalisation. PCR conditions were 95ºC for 10 min, 207 
followed by cDNA amplification for 50 cycles with 95ºC denaturation for 10s, 60ºC annealing for 208 
30 s and 72ºC elongation for 10s followed by cooling period of 30 s at 40 °C. Relative quantification 209 
using 2-∆∆CT method used to calculate differences between groups (Livak & Schmittgen 2001). 210 
 211 
Statistical analyses  212 
Results were analysed using Prism (GraphPad Software Inc., USA) and data expressed as mean ± 213 
S.E.M. For metabolic data, statistical analyses were performed using one-way ANOVA followed by 214 
Student-Newman-Keuls post-hoc test. For novel object recognition and immunohistochemistry, 215 
statistical analyses were carried out using unpaired Student’s t-test (non-parametric, with two-tailed 216 
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p values and 95% confidence interval) and one-way ANOVA with Bonferroni post-hoc test. Groups 217 
of data were considered to be significantly different if p<0.05.  218 
 219 
Results 220 
Effects of DAPA-Lira on body weight, energy intake, glucose and insulin concentrations  221 
Compared to HF controls, DAPA-Lira treatment resulted in significant time-dependent decrease in 222 
body weight (p<0.001; Fig. 1A). Importantly, body weights for DAPA-Lira and dapagliflozin 223 
groups were reduced despite no reduction in energy intake (Fig. 1B). Liraglutide-treated mice 224 
displayed reduced cumulative energy intake (p<0.05-p<0.001; Fig. 1B) compared to HF controls. 225 
DAPA-Lira treatment resulted in time-dependent decrease (242%; p<0.001) in glucose 226 
concentrations compared to HF controls, dapagliflozin or liraglutide alone (157-172%; p<0.01) on 227 
day 28 (Fig. 1C). All treatments exhibited progressive time-dependent increase in insulin but no 228 
significance was detected between HF groups, except DAPA-Lira treated mice which exhibited 229 
lower levels on day 28 (p<0.01; Fig. 1D).  230 
 231 
Effects of DAPA-Lira on glucose tolerance, insulin response to glucose, insulin sensitivity, 232 
HbA1c and plasma glucagon 233 
Mice treated with DAPA-Lira for 28 days exhibited significant reduction (37-47% decrease; p<0.01) 234 
in glucose concentrations (individual time-course for up to 120 min) compared with dapagliflozin or 235 
liraglutide alone (Fig. 2A). This was further corroborated by significantly reduced glucose AUC120 236 
values (37-52% decrease; p<0.001; Fig. 2B). As shown in Fig. 2C, all treatment groups 237 
demonstrated increased insulinotropic response, with DAPA-Lira mice exhibiting significantly 238 
higher AUC90 values (1.1-1.4-fold increase; p<0.01-p<0.001) compared to dapagliflozin or 239 
liraglutide alone (Fig. 2D). Similarly, all treatment groups displayed marked improvement in insulin 240 
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sensitivity compared to HF controls following administration of exogenous insulin (p<0.05; Fig. 241 
3A-B). DAPA-Lira treated mice also displayed marked reduction (73% lower; p<0.05) in HOMA-242 
IR compared to dapagliflozin or liraglutide alone (Fig. 3C). Furthermore, mice treated with DAPA-243 
Lira had a significantly improved HOMA-β index compared to dapagliflozin (53% increase; 244 
p<0.01) or liraglutide (13% increase; p<0.05) alone (Fig. 3D). All treatment groups had significantly 245 
(p<0.001) reduced HbA1c values compared to HF controls with DAPA-Lira treated mice exhibiting 246 
improved HbA1c (19-26% reduction; p<0.001) compared to dapagliflozin or liraglutide alone (Fig. 247 
3E). Dapagliflozin and DAPA-Lira groups had significantly increased plasma glucagon 248 
concentrations (24-33%; p <0.001) compared to HF controls, whereas liraglutide group exerted a 249 
33% reduction in plasma glucagon (p<0.001) compared to DAPA-Lira treated mice (Fig. 3F). 250 
 251 
Effects of DAPA-Lira on body composition and lipids 252 
DEXA analysis revealed that all treatment groups exhibited significant reduction (37-42% decrease; 253 
p<0.05-p<0.001) in percentage fat mass compared to HF controls (Fig. 4A). No significant 254 
differences were noted between DAPA-Lira and liraglutide or dapagliflozin. Similarly, no 255 
significant differences were observed in lean mass for any groups tested (Fig. 4B). Compared with 256 
HF controls, all treatments significantly decreased triglycerides (p<0.5-p<0.001; Fig. 4C). DAPA-257 
Lira reduced triglycerides (71-87% decrease; p<0.01-p<0.001; Fig. 4C) to a greater extent than 258 
either liraglutide or dapagliflozin alone. No significant differences between HF groups in terms of 259 
total cholesterol was observed (Fig. 4D). 260 
 261 
Effects of DAPA-Lira on terminal organ weight, hormones and biomarkers 262 
Administration of DAPA-Lira and dapagliflozin resulted in a significant reduction in inguinal 263 
adipose weight (p<0.05; Fig. 5A). Liver and pancreatic weights were not significantly different in 264 
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any of the HF groups (Fig. 5B and 5C). Total plasma GLP-1 concentrations were significantly 265 
increased in all treatment groups (p<0.001) compared to HF controls with DAPA-Lira group 266 
displaying increased levels of total GLP-1 (12-18% increase; p<0.01-p<0.001) compared to 267 
liraglutide or dapagliflozin alone (Fig. 5D). No significant differences were noted in ALT levels in 268 
HF mice (Fig. 5E). Both dapagliflozin and DAPA-Lira treatment groups displayed significantly 269 
elevated (1.0-fold; p<0.01-p<0.001) plasma IL-6 levels compared to HF controls (Fig. 5F). 270 
Liraglutide only treated mice displayed reduced (48% decrease; p<0.001) IL-6 levels compared to 271 
DAPA-Lira treatment (Fig. 5F). All treatment groups resulted in significant reduction (33-43% 272 
decrease; p<0.05) in corticosterone concentrations compared to HF controls (Fig. 5G). 273 
 274 
Effects of DAPA-Lira in novel object recognition task 275 
During test trial, no significant difference was noted in the recognition index (RI) for the HF group 276 
indicating that they could not discriminate between novel and familiar object thereby exhibiting 277 
impaired cognition (Fig. 6A). All treatment groups and lean control group displayed significantly 278 
increased RI (1.1-1.3-fold; p<0.01-p<0.001) when exposed to novel object compared to HF controls, 279 
thus highlighting preference to explore novel versus familiar object (Fig. 6B-6F). Open field 280 
assessment revealed no effect of any treatments on motor activity (speed and path length), anxiety 281 
(grooming events) and exploration (rearing events) (data not shown). 282 
 283 
Effects of DAPA-Lira on islet morphology, pancreatic hormone content and mRNA gene 284 
expression 285 
As shown in Fig. 7A, beta cell area was significantly increased (p<0.05) in liraglutide treated mice. 286 
Mice treated with dapagliflozin alone exhibited marked increase (p<0.01) in alpha cell area 287 
compared to HF controls (Fig. 7D). In contrast, DAPA-Lira or liraglutide alone did not affect alpha 288 
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cell area (Fig. 7D). Islets of HF mice exhibited substantial staining for IL-6 in beta cells and GLP-1 289 
in alpha cells with no appreciable differences between various treatment groups (images not shown). 290 
Both DAPA-Lira and liraglutide markedly increased (1.4-1.6 fold; p<0.05) pancreatic insulin 291 
content compared to HF controls (Fig. 7B). Liraglutide treatment also significantly decreased (23% 292 
reduction; p<0.001) glucagon content while both DAPA-Lira and dapagliflozin led to significant 293 
increases compared to HF controls (21-28% increase; p<0.01-p<0.001; Fig. 7E). A similar pattern to 294 
changes in pancreatic insulin and glucagon content were observed in pancreatic mRNA expression 295 
of insulin and glucagon (Fig. 7C and 7F). 296 
 297 
Effects of DAPA-Lira on neurogenesis and synaptic density 298 
Representative micrographs of doublecortin and synaptophysin staining are shown in Fig. 8A-8E. 299 
Mice treated with DAPA-Lira, dapagliflozin or liraglutide displayed increased number of immature 300 
neurons in the dentate gyrus (44-69% increase; p<0.01-p<0.001; Fig. 8F) compared to HF controls 301 
as indicated by increased number of DCX-positive cells. Significantly higher levels of 302 
synaptophysin expression were demonstrated in all treatment groups in stratum oriens layer (88-303 
113% increase; p<0.01; Fig. 8J) compared to HF controls. DAPA-Lira treatment also improved 304 
synaptophysin expression in stratum pyramidale layer (50% increase; p<0.05; Fig. 8I), though no 305 
differences in polymorph layer (Fig. 8G) and stratum radiatum (Fig. 8H) were observed. 306 
 307 
Discussion 308 
Given the increase and diversity of new antidiabetic drugs in the clinic, there is now a great 309 
opportunity to offer a more patient-centered tailored or personalized approach to therapeutic 310 
intervention. In this study, we examined the efficacy of combination therapy using the SGLT2 311 
inhibitor dapagliflozin and the long-acting GLP-1 agonist liraglutide. In addition to assessing 312 
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metabolic outcomes, we also examined potential neuroprotective benefits of combination therapy on 313 
learning and memory, especially since recent evidence has shown that GLP-1 agonists may reduce 314 
cognitive decline in diabetes-obesity (Gault et al. 2010, Porter et al. 2013). 315 
We chose to use a rodent model of diabetes combining low-dose STZ and high fat feeding to 316 
promote obesity, insulin resistance and hyperglycaemia (Srinivasan et al. 2005, Islam & Wilson 317 
2012). This rodent model has been used previously and serves as a suitable means to evaluate 318 
potential drug intervention (Bhat et al. 2013, Millar et al. 2016). A small dose of STZ was combined 319 
with high fat feeding to inflict sub-lethal damage to beta cells which when combined with high fat 320 
feeding gave a more rapid and pronounced diabetes phenotype with elevation in blood glucose 321 
concentrations. SGLT2 inhibitors act by reabsorbing glucose so it is useful to study therapeutic 322 
effects when glucose levels are significantly raised. In contrast to liraglutide, DAPA-Lira 323 
combination therapy over 28 days did not affect energy intake. This is an important observation as 324 
several studies suggested that energy intake is increased following SGLT2 inhibitor therapy 325 
(Devenny et al. 2012, Nagata et al. 2013). As expected, all treatments resulted in reduced body 326 
weight, which in the case of dapagliflozin most presumably reflects energy loss via urinary glucose 327 
excretion (Scheen & Paquot 2014). SGLT2 inhibitors induce a significant and durable weight loss in 328 
patients with T2DM (Bailey et al. 2015). 329 
Consistent with previous studies, monotherapy with dapagliflozin or liraglutide decreased 330 
glucose concentrations both in terms of non-fasting concentrations and following an oral glucose 331 
challenge. Moreover, DAPA-Lira combination therapy resulted in a more pronounced glucose-332 
lowering effect that is most likely achieved through increased urinary glucose excretion (Bailey et 333 
al. 2016) and enhanced beta cell function. Interestingly, dapagliflozin monotherapy was also 334 
associated with enhanced glucose-induced insulin secretion and HOMA-β, which could be due to 335 
improved metabolic control and reversal of beta cell glucotoxicity, a potential direct effect on beta 336 
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cells and possible involvement of effects on other hormones such as GLP-1 as observed with less 337 
selective SGLT2 inhibitors (Zambrowicz et al. 2013). Indeed, plasma GLP-1 concentrations were 338 
significantly increased in all treatment groups at the end of the study but most notably in the group 339 
receiving DAPA-Lira combination therapy. This may well point to enhanced alpha cell GLP-1 340 
production, which has been observed previously in pregnancy and situations of beta cell stress 341 
(Moffett et al. 2014, Vasu et al. 2014). Interestingly, IL-6 which has been implicated in islet 342 
processing of proglucagon to GLP-1 via increased expression of PC1/3 (Ellingsgaard et al. 2011) 343 
was markedly increased in beta cells of all HF groups. 344 
All treatment groups exhibited improved insulin sensitivity and improved HOMA-IR. These 345 
changes in insulin sensitivity may be ascribed to weight reduction and alleviation of glucose toxicity 346 
(Macdonald et al. 2010). Of particular note is the observation that DAPA-Lira combination therapy 347 
markedly reduced HbA1c, which was significantly lower than either dapagliflozin or liraglutide 348 
alone. Importantly, no episodes of hypoglycaemia were observed in treatment groups following 349 
fasting for OGTT or during the insulin tolerance test, however measurement of circulating ketones 350 
would have been informative. Taken together, DAPA-Lira combination therapy was associated with 351 
improved glucose-lowering and greater reduction in body weight (compared to liraglutide alone), 352 
without observable effects on energy intake, suggesting that combination of dapagliflozin and 353 
liraglutide is a very powerful approach to management of glycaemia. 354 
Consistent with previous studies, high fat fed mice exhibited dyslipidaemia and obesity 355 
(Podrini et al. 2013). DEXA scanning revealed that fat mass was significantly reduced in all 356 
treatment groups with tendency to be lower in groups treated with dapagliflozin and this was further 357 
corroborated by significantly decreased adipose tissue mass. In T2DM patients, body weight loss 358 
induced by dapagliflozin is mainly due to reduction in visceral and subcutaneous fat mass (Bolinder 359 
et al. 2012). Importantly, decreases in fat mass were not associated with changes in lean mass. High 360 
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fat mice displayed elevated triglyceride concentrations that were significantly improved in all 361 
treatment groups but especially in DAPA-Lira combination group. This could be due to function of 362 
improved glycaemia and greater weight reduction in this group. No significant changes in plasma 363 
total cholesterol were noted in any of the treatment groups. Although not measured in this study, 364 
relatively small clinically insignificant increases in both LDL- and HDL-cholesterol have been 365 
observed in patients on dapagliflozin therapy (Matthaei et al. 2015). As expected, HF mice exhibited 366 
increased liver weight and ALT concentrations characteristic of non-alcoholic fatty liver disease 367 
(Ganz et al. 2014). Whilst all treatments tended to reverse negative effects towards that of healthy 368 
controls, more detailed analyses investigating effects on hepatic triglyceride content, plasma and 369 
liver oxidative stress would be useful. 370 
Mice treated with dapagliflozin, either alone or in combination with liraglutide, displayed 371 
elevated levels of IL-6. IL-6 has been shown to stimulate insulin from beta cells, glucagon from 372 
alpha cells and GLP-1 secretion from both intestinal L and pancreatic alpha cells (Ehses et al. 2007, 373 
Ellingsgaard et al. 2008, 2011). Increase in GLP-1 production is thought to occur via differentiation 374 
of the alpha cell through proglucagon transcription and enhanced PC1/3 expression (Ellingsgaard et 375 
al. 2008, 2011). Furthermore, SGLT2 inhibition promotes glucagon secretion from alpha cells in 376 
healthy mice (Bonner et al. 2015) and increases GLP-1 concentrations in patients (Ferrannini et al. 377 
2014). More recent studies have suggested that dapagliflozin stimulates GLP-1 and IL6 secretion 378 
from pancreatic islets (Timper et al. 2016). In the present study, dapagliflozin increased plasma 379 
GLP-1, glucagon and IL-6, perhaps pointing to an important role for IL6 in beneficial action of 380 
dapagliflozin. Indeed, we have recently demonstrated increased expression of PC1/3 in αTC1.9 cells 381 
treated with dapagliflozin (unpublished observations). Measures of additional circulating cytokines 382 
(e.g. TNFα and IL-1β) would provide insight as to whether this reflects a specific effect on IL-6, or 383 
a more generalized heightened inflammatory state. The increase in plasma IL-6 following 384 
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dapagliflozin therapy is particularly interesting and further studies exploring its role are clearly 385 
warranted. Importantly, mice treated with liraglutide alone displayed decreased plasma glucagon 386 
with no change in IL-6 concentrations. 387 
Pancreatic immunochemical staining revealed that mice treated with dapagliflozin exhibited 388 
a significant increase in alpha cell area. This was accompanied by reduction in pancreatic insulin 389 
content and increases in both proglucagon gene expression and pancreatic glucagon content. These 390 
observations are broadly in line with metabolic insulin and glucagon data and further confirm an 391 
important effect of dapagliflozin on the alpha cell (Bonner et al. 2015). As expected, liraglutide 392 
treatment was associated with enhanced beta cell area and increased insulin content and this was 393 
accompanied by significant decrease in gene expression and pancreatic glucagon content 394 
(Schwasinger-Schmidt et al. 2013). Interestingly, alpha cell area was not affected in mice receiving 395 
DAPA-Lira combination therapy with both insulin gene expression and hormone content increased, 396 
suggesting that the liraglutide component countered some of the alpha cell promoting properties of 397 
dapagliflozin, which would be beneficial in a longer-term treatment regimen. We did not see tight 398 
correlation between the various parameters (percentage islet cells, hormone content and basal 399 
hormone levels) because many different factors influence these parameters. For example, if cell 400 
synthesizes hormone it is not just leaked out into the blood but is stored in vesicles that are regulated 401 
on minute-to-minute basis by prevailing blood glucose plus myriad of other factors. 402 
We and others have previously shown that high fat feeding in rodents causes detrimental 403 
effects in brain regions associated with learning and memory (Greenwood & Winocur 2005, 404 
Stranahan et al. 2008a, Gault et al. 2010). Furthermore, growing evidence indicates that diabetes 405 
and obesity increase the risk of developing neurodegenerative disorders, such as Alzheimer’s 406 
disease (Rani et al. 2016). More recently, GLP-1 agonists (and DPP4 inhibitors) have been shown to 407 
reduce cognitive decline associated with diabetes-obesity (Groeneveld et al. 2016). The present 408 
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study evaluated learning and memory using well-established novel object recognition task, which 409 
exploits ability of a rodent to explore a novel object over a familiar object (Abbas et al. 2009). As 410 
expected, HF mice could not discriminate between familiar and novel object when compared to 411 
healthy controls (Gault et al. 2015). However, all HF treated mice displayed significantly improved 412 
recognition memory, which was not attributable to effects on anxiety or motor activity, as indicated 413 
in open field assessment. Future studies using additional behavioural tests such as Morris Water 414 
Maze would also be useful. 415 
Corticosterone concentrations were markedly raised following high fat feeding but treatment 416 
with dapagliflozin or liraglutide (both alone and in combination) reversed this effect. Raised 417 
glucocorticoid concentrations not only induce insulin resistance but also contribute to deficits in 418 
hippocampal function (Stranahan et al. 2008b). Indeed, reducing corticosterone concentrations can 419 
prevent diabetes-induced impairment of hippocampus-dependent learning (Stranahan et al. 2008c). 420 
Immunohistochemical staining revealed that HF treated mice displayed significantly enhanced 421 
doublecortin and synaptophysin expression indicating possible role of drug treatment to promote 422 
recovery of neurogenesis and synaptic density. It is possible that combination therapy over a longer 423 
time period may have resulted in superior neurogenesis and cognitive function compared to 424 
monotherapy. To our knowledge, this is the first study to report beneficial effects of dapagliflozin on 425 
cognitive function, neurogenesis, and synaptic density. Whilst positive neuroprotective and growth 426 
factor like effects of dapagliflozin on learning and memory are unlikely to occur as direct effect of 427 
SGLT2 inhibition in the brain itself, SGLT2 inhibitors are lipid-soluble and should cross the blood-428 
brain-barrier (Bakris et al. 2009). However, similar to DPP4 inhibitors, it is plausible that 429 
neuroprotective effects observed for dapagliflozin could be attributed to increased GLP-1 430 
concentrations which can then cross the blood-brain-barrier and/or actions of dapagliflozin to lower 431 
corticosterone concentrations. Whilst we cannot rule out that part of the neuroprotective effects may 432 
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be dependent on improved peripheral glycaemia, further detailed studies to delineate mechanism for 433 
this improvement in cognitive function with dapagliflozin would be useful. 434 
In summary, compared with either agent alone, DAPA-Lira combination therapy was 435 
associated with superior glucose-lowering and significant reduction in body weight, indicating 436 
powerful and complementary approach to effectively manage hyperglycaemia. Part of this benefit 437 
appears to derive from the ability of liraglutide to decrease islet alpha cells. Other prominent effects 438 
included normalisation of hypertriglyceridaemia and enhancements of both insulin secretion and 439 
action. Furthermore, DAPA-Lira combination therapy, and indeed dapagliflozin monotherapy, were 440 
effective in reversing memory impairment in diabetic mice. Moreover, changes in glucagon and 441 
GLP-1 following dapagliflozin treatment were associated with changes in IL-6, suggesting possible 442 
role of IL-6 in mediating some of the actions of SGLT2 inhibition. This study supports recent papers 443 
showing clinical effectiveness of combination therapy with SGLT2 inhibition and stable GLP-1 444 
mimetics in T2DM patients (DeFronzo 2017). Taken together, our results highlight an important 445 
personalised approach in utilising liraglutide in combination with dapagliflozin for further clinical 446 
evaluation in the treatment of diabetes and associated neurodegenerative disorders. 447 
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Figure legends 1 
Figure 1: Effects of once-daily administration of DAPA-Lira on (A) body weight, (B) cumulative 2 
energy intake, (C) glucose and (D) insulin concentrations. HF mice received saline vehicle (0.9% 3 
wt/vol; p.o.), dapagliflozin (1 mg/kg; p.o.), dapagliflozin (1 mg/kg; p.o.) plus liraglutide (25 4 
nmol/kg; i.p) or liraglutide alone (25 nmol/kg; i.p) over 28 days. Lean control mice received saline 5 
vehicle once-daily. Metabolic parameters were measured every 3 to 4 days. Values are means ± 6 
SEM for groups of 8-10 mice. *p<0.05, **p<0.01 and ***p<0.001 compared to HF controls. 7 
∆∆
p<0.01 compared to DAPA-Lira. 8 
 9 
Figure 2: Effects of once-daily administration of DAPA-Lira on (A and B) glucose tolerance and (C 10 
and D) insulin response to glucose. HF mice received saline vehicle (0.9% wt/vol; p.o.), 11 
dapagliflozin (1 mg/kg; p.o.), dapagliflozin (1 mg/kg; p.o.) plus liraglutide (25 nmol/kg; i.p) or 12 
liraglutide alone (25 nmol/kg; i.p) over 28 days. Lean control mice received saline vehicle once-13 
daily. Glucose and insulin concentrations were measured prior to and after oral administration of 14 
glucose (18 mmol/kg) in 12-hour fasted mice. Glucose and insulin AUC values post-injection are 15 
also shown. Values are means ± SEM for groups of 8-10 mice. *p<0.05, **p<0.01 and ***p<0.001 16 




p<0.001 compared to DAPA-Lira. 17 
 18 
Figure 3: Effects of once-daily administration of DAPA-Lira on (A and B) insulin sensitivity, (C) 19 
HOMA-IR, (D) HOMA-β, (E) HbA1c and (F) plasma glucagon. HF mice received saline vehicle 20 
(0.9% wt/vol; p.o.), dapagliflozin (1 mg/kg; p.o.), dapagliflozin (1 mg/kg; p.o.) plus liraglutide (25 21 
nmol/kg; i.p) or liraglutide alone (25 nmol/kg; i.p) over 28 days. Lean control mice received saline 22 
vehicle once-daily. Parameters were measured at the end of the study period. For insulin sensitivity, 23 
glucose concentrations were measured prior to and after injection of insulin (25 U/kg; i.p.) in non-24 
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fasted mice. Glucose AAC values post-injection are also shown. Values are means ± SEM for 25 




p<0.01 and 26 
∆∆∆
p<0.001 compared to DAPA-Lira. 27 
 28 
Figure 4: Effects of once-daily administration of DAPA-Lira on (A) fat mass, (B) lean mass, (C) 29 
triglycerides and (D) total-cholesterol. HF mice received saline vehicle (0.9% wt/vol; p.o.), 30 
dapagliflozin (1 mg/kg; p.o.), dapagliflozin (1 mg/kg; p.o.) plus liraglutide (25 nmol/kg; i.p) or 31 
liraglutide alone (25 nmol/kg; i.p) over 28 days. Lean control mice received saline vehicle once-32 
daily. Parameters were measured at the end of the study period. Values are means ± SEM for groups 33 





compared to DAPA-Lira. 35 
 36 
Figure 5: Effects of once-daily administration of DAPA-Lira on (A) adipose weight, (B) liver 37 
weight, (C) pancreatic weight, (D) total GLP-1, (E) ALT, (F) corticosterone, and (G) IL-6 38 
concentrations. HF mice received saline vehicle (0.9% wt/vol; p.o.), dapagliflozin (1 mg/kg; p.o.), 39 
dapagliflozin (1 mg/kg; p.o.) plus liraglutide (25 nmol/kg; i.p) or liraglutide alone (25 nmol/kg; i.p) 40 
over 28 days. Lean control mice received saline vehicle once-daily. Parameters were measured at 41 
the end of the study period. Values are means ± SEM for groups of 8-10 mice. *p<0.05, **p<0.01 42 




p<0.001 compared to DAPA-Lira. 43 
 44 
Figure 6: Effects of once-daily administration of DAPA-Lira on recognition index for (A) HF, (B) 45 
DAPA, (C) DAPA-Lira, (D) Lira, (E) lean mice and (F) difference score. HF mice received saline 46 
vehicle (0.9% wt/vol; p.o.), dapagliflozin (1 mg/kg; p.o.), dapagliflozin (1 mg/kg; p.o.) plus 47 
liraglutide (25 nmol/kg; i.p) or liraglutide alone (25 nmol/kg; i.p) over 28 days. Lean control mice 48 
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received saline vehicle once-daily. Parameters were measured at the end of the study period. Values 49 
are means ± SEM for groups of 8-10 mice. *p<0.05, **p<0.01 and ***p<0.001 compared to HF 50 
controls. 
∆
p<0.05 compared to DAPA-Lira. 51 
 52 
Figure 7: Effects of once-daily administration of DAPA-Lira on (A) beta cell area, (B) insulin 53 
content, (C) insulin mRNA expression, (D) alpha cell area, (E) glucagon content and (F) glucagon 54 
mRNA expression. HF mice received saline vehicle (0.9% wt/vol; p.o.), dapagliflozin (1 mg/kg; 55 
p.o.), dapagliflozin (1 mg/kg; p.o.) plus liraglutide (25 nmol/kg; i.p) or liraglutide alone (25 56 
nmol/kg; i.p) over 28 days. Lean control mice received saline vehicle once-daily. Parameters were 57 
measured at the end of the study period. Values are means ± SEM for groups of 8-10 mice. *p<0.05, 58 




p<0.001 compared to DAPA-59 
Lira. 60 
 61 
Figure 8: Effects of once-daily administration of DAPA-Lira on (A-E) brain 62 
immunohistochemistry, (F) doublecortin neuroblast, and quantification levels of synaptophysin 63 
expression in (G) polymorph layer, (H) stratum radiatum, (I) stratum pyramidale and (J) stratum 64 
oriens layer. HF mice received saline vehicle (0.9% wt/vol; p.o.), dapagliflozin (1 mg/kg; p.o.), 65 
dapagliflozin (1 mg/kg; p.o.) plus liraglutide (25 nmol/kg; i.p) or liraglutide alone (25 nmol/kg; i.p) 66 
over 28 days. Lean control mice received saline vehicle once-daily. Parameters were measured at 67 
the end of the study period. Values are means ± SEM for groups of 6 mice.  *p<0.05, **p<0.01 and 68 
***p<0.001 compared to HF controls.  69 
 70 
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